In DepthBiosecurity

Critics see only risks, no benefits in horsepox paper

See allHide authors and affiliations

Science  26 Jan 2018:
Vol. 359, Issue 6374, pp. 375-376
DOI: 10.1126/science.359.6374.375

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


A highly controversial study in which researchers synthesized the horsepox virus from scratch was finally published in PLOS ONE on 19 January. The study stirred alarm when Science first reported about it in July 2017 because it might give would-be terrorists a recipe to construct smallpox virus, a major human scourge vanquished in 1980. And now that the paper is out, many scientists say it doesn't answer the most pressing question: Why did they do it? The team claims its work, funded by Tonix, a pharmaceutical company headquartered in New York City, could lead to a safer, more effective vaccine against smallpox. But safe smallpox vaccines already exist, and critics say there is no market for a horsepox-based replacement.